home / stock / tenx / tenx quote
Last: | $3.46 |
---|---|
Change Percent: | -2.57% |
Open: | $3.59 |
Close: | $3.46 |
High: | $3.59 |
Low: | $3.45 |
Volume: | 22,905 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.46 | $3.59 | $3.46 | $3.59 | $3.45 | 22,905 | 05-31-2024 |
$3.5 | $3.58 | $3.5 | $3.6 | $3.46 | 9,229 | 05-30-2024 |
$3.535 | $3.51 | $3.535 | $3.5908 | $3.5 | 12,707 | 05-29-2024 |
$3.5 | $3.512 | $3.5 | $3.61 | $3.5 | 6,468 | 05-28-2024 |
$3.51 | $3.58 | $3.51 | $3.6293 | $3.5 | 15,990 | 05-27-2024 |
$3.51 | $3.58 | $3.51 | $3.6293 | $3.5 | 15,990 | 05-24-2024 |
$3.56 | $3.56 | $3.56 | $3.74 | $3.52 | 19,037 | 05-23-2024 |
$3.62 | $3.64 | $3.62 | $3.7056 | $3.6 | 8,250 | 05-22-2024 |
$3.67 | $3.82 | $3.67 | $3.82 | $3.6058 | 14,594 | 05-21-2024 |
$3.77 | $3.6 | $3.77 | $3.7914 | $3.6 | 13,949 | 05-20-2024 |
$3.549 | $3.64 | $3.549 | $3.64 | $3.52 | 13,419 | 05-17-2024 |
$3.55 | $3.6 | $3.55 | $3.6949 | $3.54 | 32,088 | 05-16-2024 |
$3.59 | $3.61 | $3.59 | $3.61 | $3.49 | 24,168 | 05-15-2024 |
$3.47 | $3.44 | $3.47 | $3.63 | $3.44 | 52,885 | 05-14-2024 |
$3.55 | $3.51 | $3.55 | $3.65 | $3.51 | 26,112 | 05-13-2024 |
$3.585 | $3.64 | $3.585 | $3.68 | $3.47 | 10,478 | 05-10-2024 |
$3.57 | $3.64 | $3.57 | $3.64 | $3.55 | 12,452 | 05-09-2024 |
$3.55 | $3.57 | $3.55 | $3.6345 | $3.5 | 11,490 | 05-08-2024 |
$3.53 | $3.77 | $3.53 | $3.77 | $3.45 | 44,631 | 05-07-2024 |
$3.71 | $3.9 | $3.71 | $3.9 | $3.65 | 21,848 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tenax Therapeutics Inc. Company Name:
TENX Stock Symbol:
NASDAQ Market:
Tenax Therapeutics Inc. Website:
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent ...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEF ...